AMRX icon

Amneal Pharmaceuticals

8.07 USD
-0.02
0.25%
At close Jul 30, 4:00 PM EDT
After hours
8.07
+0.00
0.00%
1 day
-0.25%
5 days
0.00%
1 month
-0.25%
3 months
5.35%
6 months
-5.94%
Year to date
3.99%
1 year
11.77%
5 years
85.09%
10 years
-46.24%
 

About: Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Employees: 8,100

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

279% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 14

168% more call options, than puts

Call options by funds: $3.18M | Put options by funds: $1.19M

100% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 4 (+2) [Q1 2025]

70% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 53

19% more funds holding

Funds holding: 197 [Q4 2024] → 234 (+37) [Q1 2025]

13% more capital invested

Capital invested by funds: $997M [Q4 2024] → $1.13B (+$129M) [Q1 2025]

2.26% more ownership

Funds ownership: 40.64% [Q4 2024] → 42.9% (+2.26%) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for AMRX.

Financial journalist opinion

Based on 9 articles about AMRX published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why
Positive
Zacks Investment Research
1 day ago
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Positive
Zacks Investment Research
1 day ago
Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet
Positive
Zacks Investment Research
2 days ago
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
Neutral
GlobeNewsWire
1 week ago
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B loans (the “new term B loans”) under a new term loan facility (the “Term Loan Facility”). The Issuer has also launched an offering of $750 million aggregate principal amount of senior secured notes due 2032 (the “notes”) in a private offering.
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
Neutral
GlobeNewsWire
1 week ago
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
– Results Reflect Continued Financial Strength and Deleveraging – BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the second quarter ended June 30, 2025.
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 week ago
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted for review by Health Canada.
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
Neutral
GlobeNewsWire
3 weeks ago
Amneal to Report Second Quarter 2025 Results on August 5, 2025
BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its second quarter 2025 financial results on Tuesday, August 5, 2025, prior to market open.
Amneal to Report Second Quarter 2025 Results on August 5, 2025
Positive
Zacks Investment Research
4 weeks ago
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Neutral
GlobeNewsWire
1 month ago
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC.
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
Charts implemented using Lightweight Charts™